Ipilimumab 1 mg/kg

BIOLOGICAL2 trials

Sponsors

Merck Sharp & Dohme LLC, Baptist Health South Florida

Conditions

Non-small Cell Lung CancerRecurrent GlioblastomaSmall Cell Lung CancerSolid Tumor

Phase 1

Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)

CompletedNCT01840579

Merck Sharp & Dohme LLCNon-small Cell Lung Cancer, Small Cell Lung Cancer, Solid Tumor

Start: 2013-04-26End: 2020-02-28Updated: 2021-06-22

Phase 2

Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma

TerminatedNCT03430791

Baptist Health South FloridaRecurrent Glioblastoma

Start: 2018-12-05End: 2021-01-27Updated: 2023-02-02

Related Papers

A phase 1 study of pembrolizumab plus ipilimumab as first-line treatment in Japanese patients with advanced non-small-cell lung cancer.

2025-03-03

Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer.

2024-02-01

Phase 1 study of pembrolizumab plus chemotherapy as first-line treatment in Japanese patients with advanced NSCLC.

2021-09-153 citations